Racura Oncology (ASX:RAC) Valuation Rank


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.21
View Full Analysis

What is Racura Oncology Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Racura Oncology Valuation Rank Related Terms

ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21
Price